Sage Journals: Discover world-class research

Abstract

Pulmonary hypertension (PH) is a chronic progressive disease with high mortality. There has been more and more research focusing on the role of AMPK in PH. AMPK consists of three subunits—α, β, and γ. The crosstalk among these subunits ultimately leads to a delicate balance to affect PH, which results in conflicting conclusions about the role of AMPK in PH. It is still unclear how these subunits interfere with each other and achieve balance to improve or deteriorate PH. Several signaling pathways are related to AMPK in the treatment of PH, including AMPK/eNOS/NO pathway, Nox4/mTORC2/AMPK pathway, AMPK/BMP/Smad pathway, and SIRT3-AMPK pathway. Among these pathways, the role and mechanism of AMPK/eNOS/NO and Nox4/mTORC2/AMPK pathways are clearer than others, while the SIRT3-AMPK pathway remains still unclear in the treatment of PH. There are drugs targeting AMPK to improve PH, such as metformin (MET), MET combination, and rhodiola extract. In addition, several novel factors target AMPK for improving PH, such as ADAMTS8, TUFM, and Salt-inducible kinases. However, more researches are needed to explore the specific AMPK signaling pathways involved in these novel factors in the future. In conclusion, AMPK plays an important role in PH.

Keywords

AMPK drugs metformin pulmonary hypertension signaling pathway

Introduction

Pulmonary hypertension (PH) is a rare chronic progressive disease characterized by vascular dysfunction and structural remodeling of the pulmonary artery and the main manifestations of the body are dyspnea and fatigue.^1–4 PH is fatal and incurable at present. PH is divided into five categories, pulmonary arterial hypertension (PAH), PH caused by left ventricular diseases, PH caused by pulmonary diseases or hypoxia, PH caused by pulmonary artery obstruction, and PH caused by unknown mechanisms or multiple factors.^5–9 Though all of them have the characteristics of endothelial dysfunction and progressive accumulation of pulmonary artery vascular cells, the specific mechanism is unknown.¹⁰ It is reported that PH is related to oxidative stress, metabolic dysfunction, inflammation, vascular endothelial dysfunction, gene mutation, etc.¹¹ The AMPK is a serine/threonine (Ser/Thr) protein kinase and the function of AMPK involves abnormal proliferation of smooth muscle cells,¹² vascular endothelial dysfunction,¹³ oxidative stress,¹⁴ and metabolic dysfunction.¹⁵ Increasing studies have been confirming that AMPK is closely related to the PH. This review aims to review the role and mechanism of AMPK in PH.

The function of AMPK in PH

AMPK is composed of three subunits, namely α, β, and γ. In mammals, the α-subunit has two isoforms (α1, α2) and presents catalytic functions. The β-subunit has two isoforms (β1 and β2) and performs regulatory functions. The γ-subunit has three isoforms (γ1, γ2, and γ3) and determines the response of the AMPK complex to changes in AMP and adenosine diphosphate (ADP) and this response is sensitive to energy changes.¹⁶ In addition, all three subunits are required for the fully active expression of AMPK, but the function of AMPK is mostly related to the α subunit in PH.^16,17

AMPKα1 is more widely distributed than AMPKα2 and most of the activity of AMPK is determined by AMPKα1.^16,18 AMPKα1 is mainly expressed in pulmonary microvascular endothelial cells and smooth muscle cells, thus further increasing the expression of arginase II, which is related to the growth and proliferation of cells, promotes the proliferation of vascular smooth muscle cells and causes the occurrence of PH.^16,19 While inhibition of AMPK-α1 reduces the hypoxia-induced autophagy of pulmonary artery smooth muscle cells (PASMCs), which may be related to the inhibition of PASMCs transport and pulmonary vascular remodeling.²⁰ In addition, some studies suggest that the activation of AMPKα1 is induced by salidroside which inhibits the proliferation of PASMCs and accelerates the apoptosis of cells, thereby reducing hypoxia-induced pulmonary artery remodeling and improving PAH.²¹ Endothelial AMPKα1 deficiency enhances PH induced by hypoxia and hypoxic PH is accelerated in endothelial AMPKα1-deficient mice,^22,23 indicating that endothelial AMPKα1 plays an essential role in reducing experimental PH.²⁴

AMPKα2 is mainly expressed in endothelial cells and PASMCs.¹⁶ Similar to AMPKα1, AMPKα2 promotes the proliferation of vascular smooth muscle cells, which, in turn, leads to PH.¹⁹ Inhibition of AMPKα2 promotes hypoxia-induced apoptosis of PASMCs, thereby improving PH.²⁰

It is suggested that endothelial AMPK-α2 inhibits the development of chronic PH by inhibiting angiotensin-converting enzyme 2 (ACE2).^23,25 Moreover, AMPKα2 deficiency regulates the mTOR/Skp2/p27kip1 signaling axis to promote the proliferation of PASMCs and aggravate hypoxia-induced PH.²⁶

It is shown that a simultaneous deficiency of AMPK-α1/α2 causes neonatal persistent pulmonary hypertension (PPHN),²⁵ while a deficiency of AMPK-α1 or AMPK-α2 reduces hypoxic pulmonary vasoconstriction and fails to cause PPHN.²⁵ This suggests that there may be a crosstalk between AMPKα1 and AMPKα2, which affects PH. More studies suggested that the activation of AMPK mainly played a protective role in PH.²⁷ For example, metformin (MET) activation of AMPK may improve chronic hypoxic pulmonary hypertension, and patients with idiopathic pulmonary arterial hypertension (IPAH) show an AMPK deficiency in pulmonary arteries.^23,27–30 Previous reports suggested that AMPK may have different functions in pulmonary arteries of different diameters, different AMPK subtypes, or both.³¹ Meanwhile, the exact nature of the function triggered by the activation of AMPK may depend not only on AMPK heterotrimers but also on the type of AMPK-sensitive or AMPK-insensitive ion channels (or other protein targets) expressed by a particular cell type.³² It seems differences in the functions of AMPK subunits are related to different localization or different types of subunits; moreover, there is a crosstalk among those subunits, which ultimately triggers a delicate balance to affect the PH. Accordingly, more in-depth studies are needed to explore the role and mechanism that different AMPK localization and different catalytic isoforms may have to affect PH,¹⁹ which may enable us to find new therapeutic targets for PH.

The AMPK is activated by the decrease in cellular energy, which triggers a cascade of phosphorylation reactions of downstream molecules to inhibit the non-essential anabolic process of adenosine triphosphate (ATP) consumption and promote the catabolic pathway of the production of ATP, thereby restoring energy homeostasis.^27,33,34 In addition, AMPK is also involved in PH in many ways, like regulating the PASMCs and endothelial cells.

The proliferation of PASMCs is crucial in vascular remodeling in PH.^35–37 AMPK inhibits the proliferation of PASMCs to improve PH by regulating miR-663b,¹² AMPK/eNOS/NO signaling pathway,³⁸ YAP/FOXM1/cyclinD1 pathway,³⁹ AMPK/BMP/Smad pathway,⁴⁰ AMPK/ERK1/2/ET-1 pathway,³⁸ FGF 21/AMPK/PGC1α/PPARγ pathway,^41,42 AMPK/ p53/p21 pathway,²¹ and Nox4/mTORC2/AMPK signaling pathway.⁴³ However, there are conflicting conclusions on the role of AMPK in PH. It is suggested that AMPK promotes the proliferation of PASMCs induced by hypoxia through the ENO1-AMPK-Akt pathway to cause PH, while inhibition of AMPK improves PH.^20,44–46 It seems that the AMPK targeting different pathways results in different effects on PH.

Endothelial dysfunction frequently leads to PH. It is confirmed that AMPK improves endothelial dysfunction to inhibit PH through the AMPK-KLF2-eNOS-NO,⁴⁷ AMPK/ACE2 pathway,^30,48 and FGF21/AMPK/PGC1α/PPARγ pathway.^41,42

In addition, oxidative stress and inflammation are important causes of PH.⁴⁹ It is reported that AMPK inhibits oxidative stress and inflammation to improve PH by the AMPK/Sirt1 axis.¹²

The signaling pathway related to AMPK in PH

AMPK/eNOS/NO pathway

The AMPK/eNOS/NO pathway is mainly associated with maintaining pulmonary vascular homeostasis and is involved in PAH.⁴⁷ It is suggested that AMPK regulates Kruppel-like factor 2 (KLF2) to produce NO by endothelial nitric oxide synthase (eNOS), thus inhibiting the proliferation of PASMCs induced by superoxide. In addition, activated AMPKα1 directly regulates eNOS to inhibit the proliferation of PASMCs. Meanwhile, a high dose of NO induced by eNOS promotes apoptosis of PASMCs.⁵⁰ In addition, AMPKα1 restores endothelial dysfunction to improve vasodilation and maintain pulmonary vascular homeostasis through eNOS induced by the AMPK/eNOS/NO pathway, thereby improving PAH.^38,47,51 While the inhibition of the AMPK/eNOS/NO pathway affects pulmonary vascular homeostasis and makes PH aggravate.⁵² More importantly, NO activates AMPK by reducing cAMP 46 with PDE3A,⁴⁶ which leads to a truly vicious cycle in PH. Accordingly, the AMPK/eNOS/NO pathway is closely related to PH. The study of this pathway is relatively clear. In addition, several studies have shown that metformin, omentin, and apelin/APJ systems can improve PH through this pathway. Therefore, the AMPK/eNOS/NO pathway is a key pathway for AMPK to act on PH.

Nox4/ mTORC2/AMPK pathway

NADPH oxidase 4 (Nox4)/mTORC2/AMPK pathway is mainly related to the regulation of the proliferation of PASMCs.⁴³ It is reported that Nox4/mTORC2/AMPK pathway is involved in IPAH. Increased Nox4 protein increases the expression of mTORC2, thus downregulating AMPK, which leads to the proliferation and survival of PASMCs in IPAH due to the lack of pro-apoptotic protein, BIM; as a result, IPAH occurs.⁴³ Accordingly, the Nox4/mTORC2/AMPK pathway is an important target for the treatment of PH. Currently, the mechanism of the Nox4/ mTORC2/AMPK pathway is relatively clear and the mTOR pathway is the main growth and metabolism regulation pathway controlled by AMPK. At present, there are a number of studies on the AMPK/mTOR pathway. Accordingly, the Nox4/mTORC2/AMPK pathway is a key pathway for AMPK to act on PH.

AMPK/ACE2 pathway

The AMPK/ACE2 pathway is mainly associated with increased NO production and vasodilation.^48,53 It is reported that the AMPK/ACE2 pathway is involved in PH. Activated AMPK induces the phosphorylation of ACE2 Ser680 and reduces the ubiquitination of ACE2 to maintain the stability of ACE2. As an important regulator of the vascular protective axis of the renin-angiotensin system,^54,55 ACE2 converts Ang II into Ang-(1–7),^55–57 enhances NO production, and mediates calcium influx of microvascular endothelial cells to inhibit the vascular contraction, thereby improving PH.^30,48,53,55 Moreover, ACE2 levels decrease in the lung tissues of experimental PH animals and IPAH patients,⁵⁵ which further demonstrates that the AMPK/ACE2 pathway is involved in PH.

AMPK/BMP/Smad pathway

The AMPK/BMP/Smad pathway is mainly related to the inhibition of PASMC proliferation. It is suggested that AMPK/BMP/Smad pathway is involved in PAH. AMPK phosphorylation activated by adiponectin (APN) inhibits the PASMC proliferation induced by the BMP/Smad pathway. In addition, BMP interacts with the receptor and triggers the phosphorylation of Smad, which propagates the signal to the nucleus and regulates the expression of target genes,⁵⁸ and then causes the reduction of PASMC proliferation and finally alleviates PAH. However, the inhibition of AMPK attenuates BMP/Smad-dependent proliferation inhibition, which ultimately promotes PAH.⁴⁰ Accordingly, the AMPK/BMP/Smad pathway is closely related to PAH. The BMP signaling pathway is a key mechanism that affects pulmonary vascular remodeling. Moreover, several drugs, such as sildenafil and prostacyclin, improve PH through upregulation of the BMP signaling pathway. Accordingly, the AMPK/BMP/Smad pathway has great potential for research.^59,60

AMPK/ERK1/2/ET-1 pathway

The AMPK/ERK1/2/ET-1 pathway is mainly related to the regulation of vasoconstriction.⁶¹ It is suggested that the AMPK/ERK1/2/ET-1 pathway is involved in PH induced by hypoxia. Activated AMPK leads to the decrease in the phosphorylation level of ERK1/2 to reduce the endothelin-1 (ET-1),⁶² thereby inhibiting vasoconstriction and PASMC proliferation, which ultimately inhibits PH.^38,63 In addition, the inhibition of AMPK phosphorylation increases both ERK1/2 phosphorylation level and ET-1 production, leading to vasoconstriction and PASMC proliferation, and ultimately promoting hypoxia-induced pulmonary hypertension (HPH).³⁸

FGF21/AMPK/PGC1α/PPARγ pathway

It is reported that fibroblast growth factor 21 (FGF21)/AMPK/PGC1α/PPARγ pathway is involved in HPH. As an important regulator of the cardiovascular system,^64,65 FGF21 activates AMPK to elevate the expression of PGC1α which is a key regulator of endothelial dysfunction.⁶⁶ Elevation of PGC1α further promotes the expression of peroxisome proliferator-activated receptor γ (PPARγ),^67,68 and then inhibits PASMC proliferation and improves endothelial dysfunction, thus slowing down PH.^41,42 In addition, inhibition of AMPK promotes PH by FGF21/AMPK/PGC1α/PPARγ pathway.^41,42 Accordingly, FGF21/AMPK/ PGC1α/PPARγ pathway is closely related to PH.

AMPK/YAP/FOXM1/cyclinD1 pathway

The AMPK/YAP/FOXM1/cyclinD1 pathway is mainly related to the regulation of PASMC proliferation.³⁹ PASMC proliferation is inhibited by the activation of the AMPK/YAP/FOXM1/cyclinD1 pathway. Serum galectin-3 (Gal-3) is elevated in patients with PAH and related to the severity of the disease.⁶⁹ Gal-3 induces the upregulation, dephosphorylation, and nuclear translocation of YAP to increase the expression of FOXM1 and cyclinD1 which is a regulator of the apoptosis genes^70,71 and cell cycle progression,⁷² ultimately leading to PASMC proliferation. Activated AMPK inhibits YAP through phosphorylation of YAP and activation of Lats1/2, which reduces the expression of FOXM1 and cyclinD1, thereby inhibiting the proliferation of PASMCs induced by gal-3 to regulate PAH.³⁹ Accordingly, the AMPK/YAP/FOXM1/cyclinD1 pathway is an important target for PAH.

AMPK/FoxO1/CAT pathway

The AMPK/FoxO1/CAT pathway is mainly related to the regulation of REDOX balance.⁷³ Studies suggest that the AMPK/FoxO1/CAT pathway is related to PPHN.^16,74 Activated AMPK increases the expression of FoxO1 and FoxO3a to promote the nuclear translocation and stable existence of FoxO1, which upregulates the CAT content and activity of pulmonary artery smooth muscle. In addition, the up-expression of CAT promotes the degradation of hydrogen peroxide, which provides some defense against oxidation in PPHN though this defense may not be sufficient to protect PASMCs from hypoxia-induced increase in lipid peroxidation. In addition, studies confirm that excessive ROS under hypoxia inhibits the activation of AMPK to promote PPHN.^16,74,75 Accordingly, the AMPK/FoxO1/CAT pathway is closely related to PPHN.

AMPK-NF-κ b pathway

The AMPK-NF-κb pathway is mainly related to autophagy function.⁷⁶ Studies have shown that the AMPK-NF-κb pathway is involved in PAH.⁷⁷ Activated AMPK inhibits the translocation of NF-κb p65 from the cytoplasm to the nucleus and then reduces the autophagy protein and inhibits NF-κb-induced autophagy and inflammatory response to improve the remodeling of the pulmonary artery,¹² thus improving PAH.⁷⁷ Accordingly, the AMPK-NF-κb pathway is closely related to PAH.

AMPK/ p53/p21 pathway

The AMPK/p53/p21 pathway is mainly involved in the regulation of PASMC proliferation.³⁹ It is reported that AMPK/p53/p21 pathway is related to PAH.⁷⁸ Activated AMPK upregulates P53 to upregulate cyclin-dependent kinase inhibitor protein 1 (p21). P53 and P21 inhibit the proliferation of PASMCs and improve PAH.²¹ In addition, the inhibition of the AMPK/p53/p21 pathway promotes the proliferation level of PASMCs, which promotes the PAH.⁷⁸ Accordingly, the AMPK/p53/p21 pathway is an important target for the treatment of PAH. The mechanism of AMPK/ p53/p21 pathway is well understood. It is reported that CPT1 related to this pathway is a new therapeutic target for PAH and salidroside is a potential drug to alleviate PAH through this pathway. Accordingly, this pathway is a key pathway for AMPK to act on PH.

ENO1-AMPK-Akt pathway

The ENO1-AMPK-Akt pathway is mainly related to the proliferation of PASMCs and metabolic transformation.⁴⁴ It is suggested that the ENO1-AMPK-Akt pathway is involved in PH. AMPKα1 activated by ENO1 activates Akt to promote PASMC proliferation, dedifferentiation, anti-apoptosis, and glycolytic metabolic transition, which leads to PH.⁴⁴ In addition, the inhibition of the ENO1-AMPK-Akt pathway reduces the excessive proliferation of PASMCs induced by hypoxia, which ultimately improves PH.⁴⁴ Accordingly, the ENO1-AMPK-Akt pathway is closely related to the treatment of PH.

SIRT3-AMPK pathway

The SIRT3-AMPK pathway is mainly associated with the protection of the cardiovascular system.^79,80 It is reported that nitrite links ROS to activate sirtuin-3 (SIRT3), thereby activating the AMPK pathway and preventing pulmonary vascular remodeling, which is beneficial to PH.⁸⁰ However, the specific mechanism of this signaling pathway in PH remains unclear.

The signaling pathways involved in PH by AMPK are summarized in Figure 1.

Figure 1.

The signal pathways related to AMPK in PH.

Drugs that target the AMPK pathway for the treatment of PH

MET

There is currently no cure for PH, although some drugs can delay its progression. At present, drugs for PH only play a supportive role in delaying, without any curative effect.^19,81 MET (Figure 3(a)) is a promising drug for the treatment of PH. It is reported that MET inhibits the NF-κb/Iκbα signaling pathway by activating AMPK to reduce the level of big endothelin (big ET-1) in rat serum and prevent the development of experimental PH induced by monocrotaline (MCT) in rats. However, the specific mechanism is unclear.⁸² In addition, MET inhibits hypoxia-induced autophagy and proliferation of PASMCs by activating the AMPK pathway to prevent PAH.⁸³ Moreover, MET inhibits the upregulation of Skp2 in PASMCs induced by ET-1 to increase the level of p27 protein, which activates the AMPK pathway to inhibit the proliferation of PASMCs, thus inhibiting PAH.⁸⁴ Meanwhile, MET promotes the expression of SMAD 2/3 through the AMPK pathway, increases the negative regulatory pathway of angiogenesis, and inhibits the development of PH.⁸⁵ In addition, MET may maintain vascular homeostasis in PH by improving vascular endothelial cell function, inhibiting pulmonary vascular endothelial cell apoptosis and vascular smooth muscle cell remodeling.^23,82 This further suggests the therapeutic effect of MET on PH. Authors suggest that inhalable MET nanoparticles/microparticles might be a new treatment for PH.⁸⁶

MET combined with other drugs

MET combined with nitrite enhances the function of AMPK and vascular remodeling to improve PAH in a rat model.²² In addition, the combination therapy may serve as a preventive treatment for heart failure-associated pulmonary hypertension (PH-HFpEF),⁸⁷ a clinical complication of metabolic syndrome with ejection fraction retention. MET combined with nitrite (Figure 3(b)) may alleviate PH-HFpEF through a broader mechanism provided by multiple organs, such as pulmonary vessels, skeletal muscle, and adipose tissue. Meanwhile, bosentan (Figure 3(c)) combined with MET reduces phenylephrine-induced pulmonary artery contraction in patients with PAH caused by systemic pulmonary shunt congenital heart disease (PAH-CHD), which may be related to increased AMPK phosphorylation.⁸⁸ These studies suggest that single targeting to AMPK or the AMPK pathway may not completely inhibit PH.

Extraction of Rhodiola

Rhodiola rosea is a worldwide plant adaptogen, which has many effects such as anti-cancer, heart protection, and improvement of cardiovascular diseases.^89,90 Its extracts and active compounds present a variety of biological functions, including immune regulation, anti-oxidation, and inhibition of cancer cell proliferation.^89,90 Salidroside (Figure 3(d)) is the main bioactive marker substance isolated from Rhodiola, which is used to alleviate acute exacerbation of PAH.⁹¹ In addition, salidroside may inhibit chronic hypoxia-induced PASMC proliferation through the AMPKα1-P53-P27/P21 pathway and increase apoptosis through the AMPKα1-P53-Bax/Bcl-2-caspase 9-caspase 3 pathway.²¹ Moreover, Rhodiola crenulata water extract (RCE) significantly inhibits PPARγ, LC3B, and ATG7, upregulates p62, inactivates the LKB1-AMPK signaling pathway, and reduces autophagy to inhibit the PAH.⁹² This suggests that Rhodiola extract is a promising drug for the treatment of PAH.

Other medications

Adiponectin, an endogenous regulator of NO production, activates AMPK and promotes small fatty acid oxidation and glucose uptake.^93,94 It is reported that adiponectin prevents endothelial dysfunction and proliferation by regulating mTOR and activating the NF-κb of B cells, which is beneficial to PH.⁹³ Novel pyrazole [3, 4-B] pyridine derivatives (HLQ2g) (Figure 3(e)) regulates soluble guanylate cyclase (sGC)-mediated vasodilation and inhibits AMPK-mediated vascular remodeling, which play a therapeutic role in PAH.⁹⁵ Compared with riociguat, a currently commonly used drug for the treatment of PH, HLQ2g has dual regulatory activity in vasodilation and inhibition of vascular remodeling, showing potential advantages.⁶⁰ As NO is the key factor of the AMPK/eNOS/NO pathway, it plays an important role in PH,^46,96 so increasing studies propose nitrate and nitrite therapies that increase NO production in the treatment of PH.^87,97,98

The effects of drugs on PH are shown in Figure 2.

Figure 2.

Effects of different drugs on PH.

The structural formulas of the different drugs are shown in Figure 3.

Figure 3.

Drug structural formula: (a) metformin, (b) nitrite, (c) bosentan, (d) salidroside, and (e) novel pyrazole [3, 4-B] pyridine derivatives.

Novel therapeutic targets related to AMPK for the treatment of PH

CPT1 promotes the proliferation of PAMSCs through the AMPK/P53/P21 pathway.⁷⁸ Accordingly, CPT1 may be a novel regulatory target for the proliferation of PAMSCs in PAH.⁷⁸ In addition, depletion of ADAMTS8 upregulates AMPK and inhibits the proliferation of PAMSCs. While recombinant ADAMTS8 induces endothelial dysfunction and matrix metalloproteinase activation in an autocrine/paracrine manner.⁹⁹ Accordingly, ADAMTS8 may be a novel target for PH. Meanwhile, TUFM is highly expressed in the media smooth muscle cells of pulmonary arterioles of MCT-induced PAH; however, TUFM presents a lack of or low expression in the inner endothelial cells. Moreover, TUFM regulates the activities of AMPK and mTOR. Consequently, TUFM partially represents a new target for inhibiting PAH.¹⁰⁰ Salt-inducible kinases (SIKs) are serine/threonine kinases belonging to the AMPK family. It has been reported that SIKs are involved in PAH, which suggests that SIKs may be a therapeutic target for PAH.⁵³ The discovery of these new targets points out a new direction for further research on the treatment of PH. However, how these new targets act through AMPK remains unclear and those signaling pathways in which they are involved are still unclear.

Conclusion

AMPK plays an important role in PH. However, the current role of AMPK in PH is contradictory. AMPK has three subunits, α, β, and γ. Different subunits have different effects on PH. In addition, there are cross-talks among these subunits, which ultimately leads to a delicate balance that affects PH. How these subunits balance and interact with each other is still unclear and more researches are needed to explore in the future. The signaling pathway of AMPK related to PH mainly includes in AMPK/eNOS/NO pathway, Nox4/mTORC2/AMPK pathway, AMPK/BMP/Smad pathway, SIRT3-AMPK pathway, etc. Among these pathways, the role and mechanism of AMPK/eNOS/NO and Nox4/mTORC2/AMPK pathways are clearer than others, while the SIRT3-AMPK pathway remains still unclear in the treatment of PH. Given the controversial dilemma regarding the role of AMPK in PH, we speculate that functional differences in AMPK subunits seem to be related to different localization of subunits, different types of subunits, different signaling pathways regulated or interactions among these subunits, which ultimately trigger a delicate balance that affects PH. This suggests that more in-depth studies are needed to explore the different localization of AMPK and the mechanism of action of different catalytic isoforms targeting different pathways in the future, which will provide a basis for the specific targeted therapies against PH. In addition, the study on MET combination therapy for PH showed that combined therapy has already obtained additional benefits compared with monotherapy, which suggests that a single targeted AMPK or AMPK pathway may not be able to completely inhibit PH and the interaction of multiple targeted AMPK pathways should be further explored in the future. Some drugs target AMPK for the treatment of PH, such as MET, MET combination, rhodiola extract, etc. Meanwhile, a single drug cannot completely cure PH, which may be related to different drugs acting on different AMPK subunits. It was reported that Rhodiola rosea extracts present multiple regulatory mechanisms for PH, which provided a direction for researchers to explore the role of different AMPK pathways. In addition, there are a variety of new targets for PH through AMPK, such as ADAMTS8, TUFM, and SIKs. However, how these new targets act through AMPK and the signaling pathways they involve are still unclear. Nevertheless, the discovery of new targets points out a new direction for further research on PH.

In conclusion, AMPK plays an important role in PH.

Footnotes

Acknowledgements

None.

Declarations

ORCID iD

Shibo Sun

References

Gelzinis

. Pulmonary hypertension in 2021: Part I – definition, classification, pathophysiology, and presentation. J Cardiothorac Vasc Anesth 2022; 36: 1552–1564.

Morris

Neves

Montezano

, et al. Notch3 signalling and vascular remodelling in pulmonary arterial hypertension. Clin Sci 2019; 133: 2481–2498.

Kim

George

. Pulmonary hypertension. Med Clin North Am 2019; 103: 413–423.

Naeije

Richter

Rubin

. The physiological basis of pulmonary arterial hypertension. Eur Respir J 2022; 59(6): 210334.

Anderson

Lau

. Pulmonary hypertension definition, classification, and epidemiology in Asia. JACC Asia 2022; 2: 538–546.

Galiè

Humbert

Vachiery

, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.

Simonneau

Montani

Celermajer

, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801913.

Fukuda

Date

Doi

, et al.; on behalf of the Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J 2019; 83: 842–945.

Park

Lee

, et al.; Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the Korean Society of Cardiology (KSC) and Korean Academy of Tuberculosis and Respiratory Diseases (KATRD). 2020 KSC/KATRD guideline for the diagnosis and treatment of pulmonary hypertension: executive summary. Tuberc Respir Dis 2022; 85: 1–10.

10.

Abdelazeem

Thuillet

, et al. AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery. Eur J Pharmacol 2023; 946: 175579.

11.

Xiao

Chen

Zhou

, et al. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis 2020; 11: 1623–1639.

12.

, et al. Exosomal miR-663b from “M1” macrophages promotes pulmonary artery vascular smooth muscle cell dysfunction through inhibiting the AMPK/Sirt1 axis. Aging 2023; 15: 3549–3571.

13.

Cheng

Shang

Liu

, et al. Activation of AMPK/miR-181b Axis alleviates endothelial dysfunction and vascular inflammation in diabetic mice. Antioxidants 2022; 11: 1137.

14.

Huang

, et al. Puerarin attenuates oxidative stress and ferroptosis via AMPK/PGC1α/Nrf2 pathway after subarachnoid hemorrhage in rats. Antioxidants 2022; 11: 1259.

15.

Reed

Kumar

, et al. Transcriptome and metabolome changes induced by bitter melon (Momordica charantia)- intake in a high-fat diet induced obesity model. J Tradit Complement Med 2022; 12: 287–301.

16.

Flores

Siques

Brito

, et al. AMPK and the challenge of treating hypoxic pulmonary hypertension. Int J Mol Sci 2022; 23(11): 6205.

17.

Yan

Zhou

, et al. Structure and physiological regulation of AMPK. Int J Mol Sci 2018; 19(11): 3534.

18.

Salt

Celler

Hawley

, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 1998; 334 (Pt 1): 177–187.

19.

Xue

Nelin

Chen

. Hypoxia induces arginase II expression and increases viable human pulmonary artery smooth muscle cell numbers via ampkα(1) signaling. Am J Physiol Lung Cell Mol Physiol 2017; 312: L568–l578.

20.

Ibe

Zhou

Chen

, et al. Adenosine monophosphate-activated protein kinase is required for pulmonary artery smooth muscle cell survival and the development of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2013; 49: 609–618.

21.

Chen

Cai

, et al. Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways. Am J Transl Res 2016; 8: 12–27.

22.

Rana

Callan

Entringer

, et al. AMP-kinase dysfunction alters notch ligands to impair angiogenesis in neonatal pulmonary hypertension. Am J Respir Cell Mol Biol 2020; 62: 719–731.

23.

Omura

Satoh

Kikuchi

, et al. Protective roles of endothelial AMP-activated protein kinase against hypoxia-induced pulmonary hypertension in mice. Circ Res 2016; 119: 197–209.

24.

Elsaie

Menon

Shrestha

, et al. Endothelial adenosine monophosphate-activated protein kinase-alpha1 deficiency potentiates hyperoxia-induced experimental bronchopulmonary dysplasia and pulmonary hypertension. Antioxidants 2021; 10: 1913.

25.

Moral-Sanz

Lewis

MacMillan

, et al. AMPK deficiency in smooth muscles causes persistent pulmonary hypertension of the new-born and premature death. Nat Commun 2022; 13: 5034.

26.

Wang

Tang

Jiang

, et al. AMPKα2 deficiency exacerbates hypoxia-induced pulmonary hypertension by promoting pulmonary arterial smooth muscle cell proliferation. J Physiol Biochem 2020; 76: 445–456.

27.

Evans

Hardie

. AMPK and the need to breathe and feed: what’s the matter with oxygen? Int J Mol Sci 2020; 21(10): 3518.

28.

Rena

Hardie

Pearson

. The mechanisms of action of metformin. Diabetologia 2017; 60: 1577–1585.

29.

Goncharov

Goncharova

Tofovic

, et al. Metformin therapy for pulmonary hypertension associated with heart failure with preserved ejection fraction versus pulmonary arterial hypertension. Am J Respir Crit Care Med 2018; 198: 681–684.

30.

Zhang

Dong

Martin

, et al. AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension. Am J Respir Crit Care Med 2018; 198: 509–520.

31.

Zhao

Song

Zou

. AMPK and pulmonary hypertension: crossroads between Vasoconstriction and vascular remodeling. Front Cell Dev Biol 2021; 9: 691585.

32.

Evans

Hardie

Peers

, et al. Hypoxic pulmonary vasoconstriction: mechanisms of oxygen-sensing. Curr Opin Anaesthesiol 2011; 24: 13–20.

33.

Tilokani

Russell

Hamilton

, et al. AMPK-dependent phosphorylation of MTFR1L regulates mitochondrial morphology. Sci Adv 2022; 8: eabo7956.

34.

González

Hall

Lin

, et al. AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control. Cell Metab 2020; 31: 472–492.

35.

Liu

Zhu

, et al. Knockdown of AMPKα2 promotes pulmonary arterial smooth muscle cells proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway. Int J Mol Sci 2016; 17: 844.

36.

Schermuly

Ghofrani

Wilkins

, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011; 8: 443–455.

37.

Liu

Shi

, et al. Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21WAF1. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 961–968.

38.

Jin

Yang

, et al. C1q/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats. Sci Rep 2021; 11: 11372.

39.

Zhang

Zhu

, et al. Activation of AMPK inhibits galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP. Mol Cell Biochem 2021; 476: 3037–3049.

40.

Luo

Zheng

Lian

, et al. Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway. Int J Mol Med 2018; 41: 51–60.

41.

Green

Murphy

Kang

, et al. Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4. Am J Physiol Lung Cell Mol Physiol 2017; 313: L371–l383.

42.

Cai

Liu

Wang

, et al. Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension. Exp Biol Med 2019; 244: 252–261.

43.

Goncharov

Kudryashova

Ziai

, et al. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation 2014; 129: 864–874.

44.

Dai

Zhou

Chen

, et al. Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway. Nat Commun 2018; 9: 3850.

45.

Moral-Sanz

Mahmoud

Ross

, et al. AMP-activated protein kinase inhibits kv 1.5 channel currents of pulmonary arterial myocytes in response to hypoxia and inhibition of mitochondrial oxidative phosphorylation. J Physiol 2016; 594: 4901–4915.

46.

Dillard

Meng

Nelin

, et al. Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells. Physiol Rep 2020; 8: e14559.

47.

Yan

Wang

Cao

, et al. Apelin/APJ system: an emerging therapeutic target for respiratory diseases. Cell Mol Life Sci 2020; 77: 2919–2930.

48.

Richards

Raizada

. ACE2 and pACE2: A pair of aces for pulmonary arterial hypertension treatment? Am J Respir Crit Care Med 2018; 198: 422–423.

49.

Crosswhite

Sun

. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 2010; 28: 201–212.

50.

Wedgwood

Black

. Molecular mechanisms of nitric oxide-induced growth arrest and apoptosis in fetal pulmonary arterial smooth muscle cells. Nitric Oxide 2003; 9: 201–210.

51.

Saqueton

Miller

Porter

, et al. NO causes perinatal pulmonary vasodilation through K+-channel activation and intracellular Ca2+ release. Am J Physiol 1999; 276: L925–L932.

52.

Chandra

Razavi

Kim

, et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011; 31: 814–820.

53.

António

Soares-da-Silva

Pires

, et al. Salt-inducible kinases: new players in pulmonary arterial hypertension? Trends Pharmacol Sci 2022; 43: 806–819.

54.

Patel

Zhong

Grant

, et al. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 2016; 118: 1313–1326.

55.

Shen

Zhang

Wang

, et al. MDM2-Mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension. Circulation 2020; 142: 1190–1204.

56.

Santos

RAS

Sampaio

Alzamora

, et al. The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 2018; 98: 505–553.

57.

Oudit

Crackower

Backx

, et al. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003; 13: 93–101.

58.

García de Vinuesa

Abdelilah-Seyfried

Knaus

, et al. BMP signaling in vascular biology and dysfunction. Cytokine Growth Factor Rev 2016; 27: 65–79.

59.

Yang

Al-Lamki

, et al. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2013; 33: 34–42.

60.

Yin

, et al. Novel pyrazolo[3,4-b] pyridine derivative (HLQ2g) attenuates hypoxic pulmonary hypertension via restoring cGKI expression and BMP signaling pathway. Front Pharmacol 2021; 12: 691405.

61.

Xing

Yan

Liu

, et al. A novel mechanism for vascular insulin resistance in normotensive young SHRs: hypoadiponectinemia and resultant APPL1 downregulation. Hypertension (Dallas, TX: 1979) 2013; 61: 1028–1035.

62.

Roskoski

Jr . ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012; 66: 105–143.

63.

Hirata

Takagi

Fukuda

, et al. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225–228.

64.

Kharitonenkov

Shiyanova

Koester

, et al. FGF-21 as a novel metabolic regulator. J Clin Investig 2005; 115: 1627–1635.

65.

Wang

Xiao

Liu

, et al. FGF21 represses cerebrovascular aging via improving mitochondrial biogenesis and inhibiting p53 signaling pathway in an AMPK-dependent manner. Exp Cell Res 2016; 346: 147–156.

66.

Wang

, et al. Suppression of endothelial PGC-1α is associated with hypoxia-induced endothelial dysfunction and provides a new therapeutic target in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2016; 310: L1233–L1242.

67.

Wang

, et al. A protective role of ciglitazone in ox-LDL-induced rat microvascular endothelial cells via modulating PPARγ-dependent AMPK/eNOS pathway. J Cell Mol Med 2015; 19: 92–102.

68.

Behringer

Trappiel

Berghausen

, et al. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 369–379.

69.

Luo

, et al. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. J Am Soc Hypertens 2017; 11: 275–289.e2.

70.

Guo

, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int 2020; 20: 545.

71.

Nestal de Moraes

Delbue

Silva

, et al. FOXM1 targets XIAP and survivin to modulate breast cancer survival and chemoresistance. Cell Signal 2015; 27: 2496–2505.

72.

Hao

Zhang

Lyu

, et al. Combined use of cyclinD1 and ki67 for prognosis of luminal-like breast cancer patients. Front Oncol 2021; 11: 737794.

73.

Mohseni

Alavian

Sadeghabadi

, et al. Therapeutic effects of Chlorella vulgaris on carbon tetrachloride induced liver fibrosis by targeting Hippo signaling pathway and AMPK/FOXO1 axis. Mol Biol Rep 2021; 48: 117–126.

74.

Awad

Nolette

Hinton

, et al. AMPK and FoxO1 regulate catalase expression in hypoxic pulmonary arterial smooth muscle. Pediatr Pulmonol 2014; 49: 885–897.

75.

Yun

Park

Kim

, et al. AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1. FEBS J 2014; 281: 4421–4438.

76.

Shang

, et al. The effects of metformin on autophagy. Biomed Pharmacother 2021; 137: 111286.

77.

Zhai

Shi

Feng

, et al. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation. Life Sci 2018; 208: 87–95.

78.

Zhuang

Lian

Huang

, et al. CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension. Mol Cell Biochem 2019; 455: 169–183.

79.

Liu

Chen

, et al. SIRT3-AMPK signaling pathway as a protective target in endothelial dysfunction of early sepsis. Int Immunopharmacol 2022; 106: 108600.

80.

Hsu

Kass

. Can nitrite AMPk up sirt-ainty to treat heart failure with preserved ejection fraction? Circulation 2016; 133: 692–694.

81.

Ferns

Wehrmacher

Serratto

. Pediatric pulmonary arterial hypertension–a review. Compr Ther 2009; 35: 81–90.

82.

Yoshida

Matsuura

Goya

, et al. Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1. Exp Ther Med 2020; 20: 149.

83.

Liu

Zhu

, et al. Metformin prevents progression of experimental pulmonary hypertension via inhibition of autophagy and activation of adenosine monophosphate-activated protein kinase. J Vasc Res 2019; 56: 117–128.

84.

Liu

Zhang

, et al. Activation of AMPK inhibits pulmonary arterial smooth muscle cells proliferation. Exp Lung Res 2014; 40: 251–258.

85.

Lacout

Marcy

El Hajjam

, et al. Metformin as possible therapy of pulmonary arterio venous malformation in HHT patients. Med Hypotheses 2015; 85: 245–248.

86.

Acosta

Abrahamson

Encinas-Basurto

, et al. Inhalable nanoparticles/microparticles of an AMPK and Nrf2 activator for targeted pulmonary drug delivery as dry powder inhalers. AAPS J 2020; 23: 2.

87.

Lai

Tabima

Dube

, et al. SIRT3-AMP-Activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation 2016; 133: 717–731.

88.

Liao

Hui

, et al. Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension. J Cardiovasc Thorac Res 2019; 11: 189–195.

89.

Zhang

Bai

, et al. Anti-inflammatory effects of Rhodiola rosea L.: a review. Biomed Pharmacother 2020; 121: 109552.

90.

Chen

Tang

Yuan

, et al. Rhodiola rosea: a therapeutic candidate on Cardiovascular Diseases. Oxid Med Cell Longev 2022; 2022: 1348795.

91.

Panossian

Wagner

. Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother Res 2005; 19: 819–838.

92.

Ren

Niu

Guo

, et al. Rhodiola crenulata extract decreases fatty acid oxidation and autophagy to ameliorate pulmonary arterial hypertension by targeting inhibition of acylcarnitine in rats. Chin J Nat Med 2021; 19: 120–133.

93.

Perrotta

Nigro

Mollica

, et al. Pulmonary hypertension and obesity: focus on adiponectin. Int J Mol Sci 2019; 20(4): 912.

94.

Hebbard

Garlatti

Young

LJT

, et al. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 2008; 68: 1407–1416.

95.

Chang

, et al. Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension. J Med Chem 2020; 63: 11215–11234.

96.

Cooper

Jevnikar

Walsh

, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998; 82: 609–614.

97.

Lundberg

Gladwin

Weitzberg

. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov 2015; 14: 623–641.

98.

Vanderpool

Gladwin

. Harnessing the nitrate-nitrite-nitric oxide pathway for therapy of heart failure with preserved ejection fraction. Circulation 2015; 131: 334–336.

99.

Omura

Satoh

Kikuchi

, et al. ADAMTS8 promotes the development of pulmonary arterial hypertension and right ventricular failure: a possible novel Therapeutic Target. Circ Res 2019; 125: 884–906.

100.

Wei

Fang

, et al. Silencing TUFM inhibits development of monocrotaline-induced pulmonary hypertension by regulating mitochondrial autophagy via AMPK/mTOR Signal pathway. Oxid Med Cell Longev 2022; 2022: 4931611.

The role and mechanism of AMPK in pulmonary hypertension

Abstract

Keywords

Introduction

The function of AMPK in PH

The signaling pathway related to AMPK in PH

AMPK/eNOS/NO pathway

Nox4/ mTORC2/AMPK pathway

AMPK/ACE2 pathway

AMPK/BMP/Smad pathway

AMPK/ERK1/2/ET-1 pathway

FGF21/AMPK/PGC1α/PPARγ pathway

AMPK/YAP/FOXM1/cyclinD1 pathway

AMPK/FoxO1/CAT pathway

AMPK-NF-κ b pathway

AMPK/ p53/p21 pathway

ENO1-AMPK-Akt pathway

SIRT3-AMPK pathway

Drugs that target the AMPK pathway for the treatment of PH

MET

MET combined with other drugs

Extraction of Rhodiola

Other medications

Novel therapeutic targets related to AMPK for the treatment of PH

Conclusion

Footnotes

Acknowledgements

Declarations

ORCID iD

References